Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study.

Callegari, Ernesto; Tse, Susanna; Doran, Angela C; Goosen, Theunis C; Shaik, Naveed

Callegari, Ernesto; Tse, Susanna; Doran, Angela C; Goosen, Theunis C; Shaik, Naveed.

Afiliación

Callegari E; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Tse S; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Doran AC; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Goosen TC; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Shaik N; Clinical Pharmacology and Bioanalytics, Pfizer Inc., La Jolla, CA, USA.

J Clin Pharmacol ; 64(1): 80-93, 2024 Jan.

Article en En | MEDLINE | ID: mdl-37731282

Asunto(s)

Inductores del Citocromo P-450 CYP3A; Rifampin; Humanos; Cetoconazol/farmacología; Citocromo P-450 CYP3A/metabolismo; Proteínas Hedgehog; Inhibidores del Citocromo P-450 CYP3A; Interacciones Farmacológicas; Modelos Biológicos

Palabras clave

AML; CYP3A4; acute myeloid leukemia; drug-drug interaction; glasdegib; physiologically based pharmacokinetic modeling

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Rifampin / Inductores del Citocromo P-450 CYP3A Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google